Wikipedia -WSS

Wikipedia

author：comprehensive 2025-09-28 00:51:25 - browse：3967

Courtesy Guardant Health

An independent panel of advisers to the Food and Drug Administration recommended the agency approve Guardant Health’s blood-based colon cancer detection test. If the agency follows the recommendation, it will clear an early hurdle for the test’s broader adoption.

The expert panel spent hours listening to presentations from Guardant, the FDA, and members of the public before voting on the screening test, called Shield. The panel’s nine voting members then voted on whether the test was safe, effective, and whether its benefits outweigh its risks, with eight, six, and seven panelists endorsing those views, respectively.

FDA approval is a requirement for winning coverage from the Centers for Medicare and Medicaid Services, which could be the difference between Guardant’s test becoming widespread — or irrelevant. In 2021, CMS denied coverage for Epi proColon, a different blood-based colon cancer test approved by the FDA. Soon after, the test’s maker, Epigenomics, announced that it would stop actively marketing the test, and last year the company announced a restructuring that included layoffs.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： After affirmative action ruling, medical educators look to 'holistic review'
Next article： FDA's Woodcock to retire early next year

explore

WSS

In Spain, a hospital brews its own CAR

Gain of function research would be limited under House proposal

Poor hospice wound care hurts patients and families

Medicare Advantage beneficiaries sue Humana over algorithm use

Weight loss drug costs may need more research, senator suggests

Buoyed by wins on obesity, Novo Nordisk eyes heart disease

Wikipedia

Wikipedia

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

entertainment

At least 13 dead in Texas as scorching temps continue

Advocates call out 'SNL' over stereotypes, errors in sickle cell skit

Drug repurposing or repositioning? The language matters

Childhood cancer progress stalls for Black, Hispanic kids: Report

What does generative AI mean for health care? We asked experts

World's first CRISPR

After affirmative action ruling, medical educators look to 'holistic review'

In key trial, Verve's treatment lowers cholesterol levels in patients

In age of alternative facts, a scholarly course on calling out crap

Does good food count as health care? Study aims to find out

focus

NYU radiologists take on the challenge of expensive MRI machines

Congress must reauthorize a committee to support older Americans

Grail spinoff by Illumina should end disastrous merger attempt

Surge of respiratory disease in China has likely explanation

FDA's Woodcock to retire early next year

Keeping primary care docs in field isn't impossible, says AAFP CEO

entertainment

focus

explore

focus